Drug interactions between proton pump inhibitors and antiretroviral drugs

• NO AUTHORS LISTED: ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am. J. Health Syst. Pharm. (1999) 56(4):347-379.
   PubMed Web of Science ®Google Scholar
• FRENKEL LM, TOBIN NH: Understanding HIV-1 drug resistance. Ther. Drug Monit. (2004) 26(2):116-121.
   PubMed Web of Science ®Google Scholar
• PATERSON DL, SWINDELLS S, MOHR J et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. (2000) 133(1):21-30.
   PubMed Web of Science ®Google Scholar
• LUCAS GM: Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J. Antimicrob. Chemother. (2005) 55(4):413-416.
   PubMed Web of Science ®Google Scholar
• FELLAY J, MARZOLINI C, MEADEN ER et al.: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 359(9300):30-36.
   PubMed Web of Science ®Google Scholar
• LUBER A, GARG V, GHARAKHANIAN S et al.: Survey of medication used by HIV-infected patients that affect gastrointestinal (GI) acidity and potential for negative drug interactions with HAART [294]. In: Seventh International Congress on Drug Therapy in HIV Infections. Glasgow, UK (2004).
   Google Scholar
• BLUM RA, SHI H, KAROL MD et al.: The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin. Ther. (1997) 19(5):1013-1023.
   PubMed Web of Science ®Google Scholar
• HATLEBAKK J: Review article: gastric acidity – comparison of esomeprazole with other proton pump inhibitors. Aliment. Pharmacol. Ther. (2003) 17(Suppl. 1):10-15.
   PubMed Web of Science ®Google Scholar
• HORN J: Review article: understanding the pharmacodunamic and pharmacokinetic differences between proton pump inhibitors – focus on pKa and metabolism. Aliment. Pharmacol. Ther. Symp. (2006) 2:340-350.
   Google Scholar
• ROBINSON M, HORN J: Clinical pharmacology of proton pump inhibitors; what the practsing physician needs to know. Drugs (2003) 63:2739-2754.
   PubMed Web of Science ®Google Scholar
• Aciphex®. Product Information. Eisai, Inc., Teaneck, NJ, USA (2003).
   Google Scholar
• MCCOLL KE, KENNERLEY P: Proton pump inhibitors – differences emerge in hepatic metabolism. Dig. Liver Dis. (2002) 34(7):461-467.
   PubMedGoogle Scholar
• MINER P Jr, KATZ PO, CHEN Y, SOSTEK M: Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am. J. Gastroenterol. (2003) 98(12):2616-2620.
   PubMed Web of Science ®Google Scholar
• ROHSS K, HASSELGREN G, HEDENSTROM H: Effect of esomeprazole 40 mg versus omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig. Dis. Sci. (2002) 47(5):954-958.
   PubMed Web of Science ®Google Scholar
• HOETELMANS R: Clinical pharmacokinetics of antiretroviral drugs. AIDS Rev. (1999) 1:167-178.
   Google Scholar
• Reyataz®. Product information. Bristol-Myers Squibb, Princeton, NJ, USA (2006).
   Google Scholar
• TOMILO DL, SMITH PF, OGUNDELE AB et al.: Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy (2006) 26(3):341-346.
   PubMed Web of Science ®Google Scholar
• AGARWALA S, GRAY K, WANG Y, GRASELA D: Pharmacokinetic effect of omperazole on atazanavir co-administered with ritonavir in healthy subjects. Presented at: The 12th conference on retroviruses and opportunistic infections. Boston, MA, USA (2005).
   Google Scholar
• KISER JJ, LICHTENSTEIN KA, ANDERSON PL, FLETCHER CV: Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy (2006) 26(4):511-514.
   PubMed Web of Science ®Google Scholar
• KOSEL BW, STOREY SS, COLLIER AC: Lack of interaction between atazanavir and lansoprazole. AIDS (2005) 19(6):637-638.
   PubMed Web of Science ®Google Scholar
• ANTONIOU T, YOONG D, BEIQUE L et al.: Impact of acid-suppressive therapy on virologic response to atazanavir-based regimens in antiretroviral-experienced patients: a case series. J. Acquir. Immune Defic. Syndr. (2005) 39(1):126-128.
   PubMed Web of Science ®Google Scholar
• WINSTON A, BLOCH M, CARR A et al.: The clinical correlation’s of trough plasma atazanavir concentrations in a cohort of HIV-1 positive individuals receiving HAART. Presented at: The 12th conference on retroviruses and opportunistic infections. Boston, MA, USA (2005).
   Google Scholar
• LUBER A, BROWER R, RELOQUIN C, FRANK I: Steady state pharmacokinetics of QD fosamprenavir/ritonavir and atazanavir/ritonavir in combination with 20mg QD omperazole in healthy volunteers. Presented at: The 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal (2006).
   Google Scholar
• AGARWALA S, ELAY T, CHILD M et al.: Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Quebec, Canada. (2005) Abstract 11.
   Google Scholar
• O’MARA E, PILIERO P, DRUSANO G et al.: BMS-32632: a preliminary pharmacokinetic and pharmacodynamic evaluation of BMS-232632 in a protease inhibitor naïve HIV+ population. AIDS (2000) 14(Suppl.4):S19.
   Web of Science ®Google Scholar
• TABURET AM, PC, CHAZALLON C et al.: Interactions between atazanavir/ritonavir and tenofovir in heavily pretreated HIV-infected patients. Antimicrob. Agents Chemother. (2004) 48:2091-2096.
   PubMed Web of Science ®Google Scholar
• AGARWALA S, RUSSO R, MUMMANENI V EA: Steady state pharmacokinetic interaction study of atazanavir with ritonavir in healthy subjects [abstract no H1716]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002).
   Google Scholar
• Prezista®. Product information. Tibotec, Bridgewater, NJ, USA (2006).
   Google Scholar
• SEKAR V, HOETELMANS R, DE MAREZ T, DE PAUW M et al.: Pharmacokinetics of TMC-114: effect of omeprazole and ranitidine. International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janerio, Brazil (2005).
   Google Scholar
• Lexiva®. Product information. GlaxoSmithKline, Research Triangle Park, NC, USA (2006).
   Google Scholar
• FURFINE ES, BAKER CT, HALE MR et al.: Preclinical pharmacology and pharmacokinetics of GW-433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob. Agents Chemother. (2004) 48(3):791-798.
   PubMed Web of Science ®Google Scholar
• SHELTON MJ, FORD SL, BORLAND J et al.: Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J. Acquir. Immune Defic. Syndr. (2006) 42(1):61-67.
   PubMed Web of Science ®Google Scholar
• FORD SL, WIRE MB, LOU Y, BAKER KL, STEIN DS: Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob. Agents Chemother. (2005) 49(1):467-469.
   PubMed Web of Science ®Google Scholar
• Crixivan®. Product information. Merck & Co., Inc., Whitehouse Station, NJ, USA (2004).
   Google Scholar
• BURGER DM, HUGEN PW, KROON FP et al.: Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. AIDS (1998) 12(15):2080-2082.
   PubMed Web of Science ®Google Scholar
• LIN JH, CHEN IW, VASTAG KJ, OSTOVIC D: pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab. Dispos. (1995) 23(7):730-735.
   PubMed Web of Science ®Google Scholar
• Videx®. Product information. Bristol-Myers Squibb, Princeton, NJ, USA (2000).
   Google Scholar
• BERTZ R, CHIU Y, NAYLOR C, LUFF K, BRUN S: Lack of effect of gastric acid reducing agents on lopinavir/ritonavir plasma concentrations in HIV-infected patients. Presented at: The 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (2004).
   Google Scholar
• Kaletra®. Product information. Abbott Laboratories, North Chicago, IL, USA.
   Google Scholar
• KLEIN C, CHIU Y, CAI Y et al.: Lack of effect of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir Tablet. Presented at: The 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA (2006).
   Google Scholar
• Invirase®. Product information. Roche Laboratories, Inc., Nutley, NJ, USA (2005).
   Google Scholar
• WINSTON A, BACK D, FLETCHER C et al.: Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS (2006) 20(10):1401-1406.
   PubMed Web of Science ®Google Scholar
• KAKUDA TN, FALCON RW: Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers. Pharmacotherapy (2006) 26(8):1060-1068.
   PubMed Web of Science ®Google Scholar
• Aptivus®. Product information. Boehringer Ingelheim, Ridgefield, CT, USA (2006).
   Google Scholar
• HEESWIJK REA: The pharmacokinetic interactions between tipranavir/ritonavir 500 mg/200 mg bid (TPV/r) and atorvastatin, antacid and CYP 3A4 in healthy volunteers. Presented at: The 5th International Workshop on Clinical Pharmacology in HIV Therapy. Rome, Italy (2004).
   Google Scholar
• Rescriptor®. Product information. Pfizer, Groton, CT, USA (2006).
   Google Scholar
• SHELTON MJ, HEWITT RG, ADAMS JM et al.: Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. J. Clin. Pharmacol. (2003) 43(2):171-179.
   PubMed Web of Science ®Google Scholar
• LAKE-BAKAAR G, QUADROS E, BEIDAS S et al.: Gastric secretory failure in patients with the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. (1988) 109(6):502-504.
   PubMed Web of Science ®Google Scholar
• WELAGE LS, CARVER PL, REVANKAR S, PIERSON C, KAUFFMAN CA: Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin. Infect. Dis. (1995) 21(6):1431-1438.
   PubMed Web of Science ®Google Scholar
• SHELTON MJ, ADAMS JM, HEWITT RG, MORSE GD: Previous infection with Helicobacter pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients. Clin. Infect. Dis. (1998) 27(4):739-745.
   PubMed Web of Science ®Google Scholar
• SHAFFER RT, LAHATTE LJ, KELLY JW et al.: Gastric acid secretion in HIV-1 infection. Am. J. Gastroenterol. (1992) 87(12):1777-1780.
   PubMed Web of Science ®Google Scholar
• OLMOS M, ARAYA V, PSKORZ E et al.: Coinfection: Helicobacter pylori/human immunodeficiency virus. Dig. Dis. Sci. (2004) 49(11-12):1836-1839.
   PubMed Web of Science ®Google Scholar
• PISCATELLI S, BAEDE P, DEGIER K, VAN ‘T KLOOSTER G, GRAHAM N: Pharmacokinetics of TMC-125 in HIV infected patients and healthy volunteers. 3rd International Workshop on Clinical Pharmacology of HIV Therapy. Washington, DC, USA April (2002).
   Google Scholar
• GRUZDEV B, RAKHMANOVA A, DOUBOVSKAYA E et al.: A randomized, double-blind, placebo-controlled trial of TMC-125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS (2003) 17(17):2487-2494.
   PubMed Web of Science ®Google Scholar
• GYURE-SCHOLLER M EA: TMC-125 bioavailability is not affected by ranitidine and omeprazole. International AIDS Society. Toronto, Canada (2006).
   Google Scholar
• BACK D, GATTI G, FLETCHER C et al.: Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS (2002) 16(Suppl. 1):S5-S37.
   PubMed Web of Science ®Google Scholar
• GERBER JG, ACOSTA EP: Therapeutic drug monitoring in the treatment of HIV infection. J. Clin. Virol. (2003) 27(2):117-128.
   PubMed Web of Science ®Google Scholar
• CLEVENBERGH P, MOULY S, SELLIER P et al.: Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinicians point of view. Curr. HIV Res. (2004) 2:309-321.
   PubMed Web of Science ®Google Scholar
• FELLAY J, MARZOLINI C, MEADEN ER et al.: Repsonse to antiretroviral treatment in HIV-1 infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 359(9300):30-36.
   PubMed Web of Science ®Google Scholar

Website

• http://AIDSinfo.nih.govPanel on Antiretroviral Guidelines for Adults and Adolescents: Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [online] (last accessed March 2007).
   Google Scholar